INDV Share PerformanceMore
|52 week high||421.50 23/08/17|
|52 week low||246.50 01/09/17|
|52 week change||111.70 (39.71%)|
|4 week volume||45,495,017 19/11/17|
Latest News« previous» nextMore
12/12/2017 - 08:06 StockMarketWire
The US Food and Drug Administration has accepted the Indivior's new drug application (NDA) for RBP-7000, an investiga...
12/12/2017 - 07:00 RNS
RNS Number: 0587Z Indivior PLC 12 December 2017 Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot A Novel Sustained-Release Candidate for Treatment of Schizophrenia Slough, UK and Richmond, VA, 12 December 2017 - Indivior PLC (LON: INDV) (the 'Company') today announces that the U.S. Food and Drug Administration (FD...
08/12/2017 - 08:13 StockMarketWire
Indivior has issued 5,000,000 ordinary shares to satisfy the vesting of share awards under its long-term incentive plan. At 8:...
08/12/2017 - 07:00 RNS
RNS Number: 7239Y Indivior PLC 08 December 2017 Indivior PLC (the "Company") - Block listing of shares Application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 5,000,000 Ordinary Shares of US$ 0.10 each to trade on the London Stock Exchange and to be admitted to the Official List. The shares will be issued...
01/12/2017 - 16:46 StockMarketWire
The price of Brent crude oil surged 2.3% to $64.10 per barrel after the oil cartel OPEC chose to extend production cuts until...
01/12/2017 - 11:58 StockMarketWire
On Thursday evening, a speech by Labour leader Jeremy Corbyn rattled investors after he said he was a 'threat' to big ban...
01/12/2017 - 08:03 StockMarketWire
The US Food and Drug Administration has approved Indivior's Sublocade for the treatment of opioid addiction. Indivior s...
01/12/2017 - 07:00 RNS
RNS Number: 1031Y Indivior PLC 01 December 2017 Attach pdf http://www.rns-pdf.londonstockexchange.com/rns/1031Y_-2017-12-1.pdf FDA Approves SUBLOCADE TM (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder SUBLOCADE Expected to be Available...
Latest discussion posts More
“It's make! For a stellar share today this gets very little chat coverage.”▼
“The opioid decision by the FDA is today eh? Any more feelings either way. It could be a make or break.”▼
“Very glad I topped up at #2.95, don't often get a 35% increase in 2 months. Thinking of top slicing, but on the whole, I think the fact that the DoJ case is well provided for, ...”▼
Codes & Symbols
|Symbols||INDV, LSE:INDV, INDV.L, INDV:LN, LON:INDV, XLON:INDV|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment